guselkumab vs SPY003
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline
guselkumab · Tremfya
Marketed by Johnson & Johnson
QUASAR/GALAXI · Phase 3 · completed
Only IL-23i to beat ustekinumab head-to-head on endoscopy in a registrational trial — strong differentiator.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2027 · NCT06260163 (registry estimate)
Reported efficacy
Percentage of Participants in Clinical Remission at Week 12: Percentage of Participants in Clinical Remission at Week 12 (Week 12): Placebo 6.5 Percentage of participants (95% CI 2.4 to 10.6) | Combined Guselkumab 400 mg 27.6 Percentage of participants (95% CI 22.4 to 32.8) (met)
Result source: NCT05528510
SPY003
Developed by Spyre Therapeutics
NCT07012395 · Phase 2 · recruiting
This was a randomized, quadruple-masked Phase 2 trial with 645 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-08. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
Next expected readout: June 2027 · NCT07012395 (registry estimate)
Reported efficacy
Part A: Change in Robarts Histopathology Index (RHI) (Week 12); Part B: Percentage of participants with clinical remission (Week 12): Part A primary endpoint (week 12): Robarts Histopathology Index reduced 10.0 points from baseline (p<0.0001) (Spyre, 2026-09-08). (met)
Result source: NCT07012395
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | guselkumab | SPY003 |
|---|---|---|
| Clinical remission (induction) | 22.6% vs 7.9%+14.7 vs placeboNCT040334452 other results
| —Not reported |
| Clinical remission (maintenance) | 50% vs 18.9%+31.1 vs placeboNCT040334451 other result
| —Not reported |
| Clinical response (induction) | 61.4% vs 27.6%+33.8 vs placeboNCT040334453 other results
| —Not reported |
| Endoscopic improvement (induction) | —Trial running · NCT04033445 | —Not reported |
| Corticosteroid-free remission (maintenance) | —Trial running · NCT04033445 | —Not reported |
Clinical remission (induction)
- guselkumab
- 22.6% vs 7.9%+14.7 vs placeboNCT04033445
2 other results
- 21.1% vs 22.2% NCT03662542
- 36.6% vs 22.2% NCT03662542
- SPY003
- —Not reported
Clinical remission (maintenance)
- guselkumab
- 50% vs 18.9%+31.1 vs placeboNCT04033445
1 other result
- 45.2% vs 18.9% NCT04033445
- SPY003
- —Not reported
Clinical response (induction)
- guselkumab
- 61.4% vs 27.6%+33.8 vs placeboNCT04033445
3 other results
- 60.7% vs 27.6% NCT04033445
- 74.6% vs 61.1% NCT03662542
- 83.1% vs 61.1% NCT03662542
- SPY003
- —Not reported
Endoscopic improvement (induction)
- guselkumab
- —Trial running · NCT04033445
- SPY003
- —Not reported
Corticosteroid-free remission (maintenance)
- guselkumab
- —Trial running · NCT04033445
- SPY003
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. guselkumab: 4 of 4 rows · SPY003: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | guselkumab |
|---|---|
| Dropout rate | 2.8%200 mg IVa NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 show 17 more results—200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 4.1%200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —100 mg SC q8w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —100 mg SC q8w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 0.9%400 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 0%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 1.4%Combination Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Monotherapy Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Safety Follow-up: Guselkumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
| Discontinued due to AEs | 0.9%200 mg IVa NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 show 17 more results—200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 1.6%200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —100 mg SC q8w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 —100 mg SC q8w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 0%400 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 0%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 1.4%Combination Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Monotherapy Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Safety Follow-up: Guselkumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
| Serious AEs | 0.9%200 mg IVa NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 show 17 more results3%200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 3.8%200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 3%200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 2.3%200 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 2.3%200 mg SC NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 6.5%200 mg SC q4w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 5.6%200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 6%200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 4.3%100 mg SC q8w to 200 mg SC q4w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 2.5%100 mg SC q8w NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 2.7%400 mg IV NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 1.4%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 2.8%Combination Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy 4.2%Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 1.4%Monotherapy Phase: Guselkumab Mono NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy 0%Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination 3.1%Safety Follow-up: Guselkumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
| Most frequent reported AEs | 200 mg IVa anaemia 7.4% (placebo 10.2%) covid-19 5.6% (placebo 4.6%) abdominal pain 3.7% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 show 17 more results200 mg IV anaemia 6% (placebo 10.2%) upper respiratory tract infection 4.5% (placebo 0%) colitis ulcerative 3% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg SC colitis ulcerative 3.8% (placebo 2.8%) headache 3.8% (placebo 7.4%) anaemia 2.5% (placebo 10.2%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg IV anaemia 5% (placebo 10.2%) covid-19 5% (placebo 4.6%) headache 3% (placebo 7.4%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg IV covid-19 7.6% (placebo 4.6%) colitis ulcerative 4.1% (placebo 2.8%) nasopharyngitis 2.9% (placebo 1.9%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg SC covid-19 7% (placebo 4.6%) colitis ulcerative 5.4% (placebo 2.8%) anaemia 4.7% (placebo 10.2%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg SC q4w to 200 mg SC q4w colitis ulcerative 16.1% (placebo 2.8%) covid-19 6.5% (placebo 4.6%) abdominal pain 3.2% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg SC q4w covid-19 18.4% (placebo 4.6%) colitis ulcerative 16.8% (placebo 2.8%) pyrexia 6.4% (placebo 4.6%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 200 mg SC q4w colitis ulcerative 13.1% (placebo 2.8%) covid-19 10.1% (placebo 4.6%) arthralgia 8% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 100 mg SC q8w to 200 mg SC q4w covid-19 13% (placebo 4.6%) anaemia 8.7% (placebo 10.2%) colitis ulcerative 8.7% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 100 mg SC q8w covid-19 14.2% (placebo 4.6%) colitis ulcerative 10.2% (placebo 2.8%) arthralgia 6.1% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 400 mg IV anaemia 8.1% (placebo 10.2%) headache 5.4% (placebo 7.4%) arthralgia 3.6% (placebo 2.8%) NCT04033445 · Phase 3 · monotherapy · Ulcerative Colitis · phase 2/3 anaemia 5.6% colitis ulcerative 5.6% headache 5.6% NCT03662542 · Phase 2 · registry result, not featured evidence · combination anaemia 8.5% upper respiratory tract infection 7% neutropenia 5.6% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy colitis ulcerative 8.5% upper respiratory tract infection 8.5% headache 4.2% NCT03662542 · Phase 2 · registry result, not featured evidence · combination anaemia 8.6% headache 7.1% colitis ulcerative 5.7% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy anaemia 0% colitis ulcerative 0% headache 0% NCT03662542 · Phase 2 · registry result, not featured evidence · combination anaemia 1.5% colitis ulcerative 1.5% headache 0% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
Notes
- aPopulation comparability has not been reviewed for 6 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
guselkumab
show 3 more results
show 4 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: guselkumab's landscape · SPY003's landscape